Drug Profile
Remlarsen - miRagen Therapeutics
Alternative Names: miR-29 replacement; MRG-201Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer miRagen Therapeutics; Yale University
- Class Antifibrotics; Eye disorder therapies; MicroRNAs; Skin disorder therapies
- Mechanism of Action Collagen inhibitors; RNA inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Fibrosis
- No development reported Eye disorders; Pulmonary fibrosis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Eye-disorders in USA (Intravitreous, Injection)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Eye-disorders in USA (Topical)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in USA (Inhalation)